Europe Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type (Proteomic, Genomic, Metabolomic), By Application (Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis), By Country and Growth Forecast, 2022 - 2028

Europe Neurological Biomarkers Market Size, Share & Industry Trends Analysis Report By Type (Proteomic, Genomic, Metabolomic), By Application (Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis), By Country and Growth Forecast, 2022 - 2028

The Europe Neurological Biomarkers Market would witness market growth of 13.7% CAGR during the forecast period (2022-2028).

With the recent development of neurological biomarkers found in blood, identifying and treating neurological diseases such as chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, autism, and major depressive disorder should become simpler. Recent developments in detection technology have made it possible to find neurological biomarkers in blood.

For instance, the Simoa (single-molecule array) technology from Quanterix increases sensitivity by digitizing the extremely effective ELISA (enzyme-linked immunosorbent test) method of measuring binding between two molecules. For the biomarker of interest, Quanterix screens patient samples using 720,000 microscopic beads covered with capture antibodies. The beads are then mixed with a fluorescent marker and spread out into 216,000 isolated microchambers.

The high signal-to-noise ratio results in very responsive detection. Numerous researchers use Quanterix's technology to evaluate biomarker quantities in both CSF and blood, with almost half of their current applications being related to neurology. One such is their work on CTE and concussion biomarkers. Mild concussions can cause brain damage without causing any symptoms, and the accumulation of multiple sub-concussive hits to the brain leads to the development of CTE.

Doctors in the UK informed the platforms of 153 unique instances that met the clinical case criteria during this time, which is comparable to the aggregate COVID-19 data from UK government public health organizations. Of the 153 patients, complete clinical data were available for 125 (82%) of them. In the UK, many people experience tinnitus, yet the illness is poorly understood and has no standard therapy. Tinnitus is thought to be brought on by aberrant nerve discharge patterns in the brain's hearing centers. These characteristics have led to a flourishing market for regional neurological biomarkers market.

The Germany market dominated the Europe Neurological Biomarkers Market by Country in 2021; thereby, achieving a market value of $822.7 Million by 2028. The UK market is experiencing a CAGR of 12.8% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 14.5% during (2022 - 2028).

Based on Type, the market is segmented into Proteomic, Genomic, Metabolomic and Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson’s Disease and Multiple Sclerosis. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. HOFFMANN-LA ROCHE LTD., Bio-Rad Laboratories, Inc., Merck Group, PERKINELMER INC., Shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix Corporation, Neuro-Bio Ltd., BioMérieux S.A. and Myriad Genetics, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Proteomic
  • Genomic
  • Metabolomic
  • Others
By Application
  • Alzheimer's Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • F. HOFFMANN-LA ROCHE LTD.
  • Bio-Rad Laboratories, Inc.
  • Merck Group
  • PERKINELMER INC.
  • Shimadzu corporation
  • Thermo Fisher Scientific, Inc.
  • Quanterix Corporation
  • Neuro-Bio Ltd.
  • BioMérieux S.A.
  • Myriad Genetics, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Neurological Biomarkers Market, by Type
1.4.2 Europe Neurological Biomarkers Market, by Application
1.4.3 Europe Neurological Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Neurological Biomarkers Market by Type
3.1 Europe Proteomic Market by Country
3.2 Europe Genomic Market by Country
3.3 Europe Metabolomic Market by Country
3.4 Europe Others Market by Country
Chapter 4. Europe Neurological Biomarkers Market by Application
4.1 Europe Alzheimer's Disease Market by Country
4.2 Europe Parkinson’s Disease Market by Country
4.3 Europe Multiple Sclerosis Market by Country
Chapter 5. Europe Neurological Biomarkers Market by Country
5.1 Germany Neurological Biomarkers Market
5.1.1 Germany Neurological Biomarkers Market by Type
5.1.2 Germany Neurological Biomarkers Market by Application
5.2 UK Neurological Biomarkers Market
5.2.1 UK Neurological Biomarkers Market by Type
5.2.2 UK Neurological Biomarkers Market by Application
5.3 France Neurological Biomarkers Market
5.3.1 France Neurological Biomarkers Market by Type
5.3.2 France Neurological Biomarkers Market by Application
5.4 Russia Neurological Biomarkers Market
5.4.1 Russia Neurological Biomarkers Market by Type
5.4.2 Russia Neurological Biomarkers Market by Application
5.5 Spain Neurological Biomarkers Market
5.5.1 Spain Neurological Biomarkers Market by Type
5.5.2 Spain Neurological Biomarkers Market by Application
5.6 Italy Neurological Biomarkers Market
5.6.1 Italy Neurological Biomarkers Market by Type
5.6.2 Italy Neurological Biomarkers Market by Application
5.7 Rest of Europe Neurological Biomarkers Market
5.7.1 Rest of Europe Neurological Biomarkers Market by Type
5.7.2 Rest of Europe Neurological Biomarkers Market by Application
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings